FMP

FMP

Enter

VCYT - Veracyte, Inc.

Financial Summary of Veracyte, Inc.(VCYT), Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequen

photo-url-https://financialmodelingprep.com/image-stock/VCYT.png

Veracyte, Inc.

VCYT

NASDAQ

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

23.92 USD

0.45 (1.88%)

About

ceo

Mr. Marc A. Stapley

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to hel...

CIK

0001384101

ISIN

US92337F1075

CUSIP

92337F107

Address

6000 Shoreline Court

Phone

650 243 6300

Country

US

Employee

815

IPO Date

Oct 30, 2013

Summary

CIK

0001384101

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

92337F107

ISIN

US92337F1075

Country

US

Price

23.92

Beta

1.64

Volume Avg.

783.52k

Market Cap

1.83B

Shares

-

52-Week

18.61-29.4

DCF

-5.54

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-25.72

P/B

-

Website

https://www.veracyte.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest VCYT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep